H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $84
Breaking Down Prothena Corp: 4 Analysts Share Their Views
A Quick Look at Today's Ratings for Prothena(PRTA.US), With a Forecast Between $24 to $84
B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $31
HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $84 Price Target
Prothena Buy Rating Affirmed: Leadership Changes and Prasinezumab's Promise Signal Investment Opportunity
Maintaining Hold on Prothena Amid Executive Changes and Clinical Validation Needs
Sector Update: Health Care Stocks Mixed in Afternoon Trading
12 Health Care Stocks Moving In Monday's Intraday Session
Update: Prothena's Shares Fall as Chief Medical Officer Departs
Prothena Down Nearly 19%, on Pace for Largest Percent Decrease Since March 2020 -- Data Talk
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $62
Oppenheimer Keeps Their Buy Rating on Prothena (PRTA)
Prothena Names Chad Swanson as Chief Development Officer; Chief Medical Officer Departs
Express News | Prothena Announces Leadership Team Updates
There Is A Reason Prothena Corporation Plc's (NASDAQ:PRTA) Price Is Undemanding
Prothena to Participate in Upcoming Healthcare Conferences
We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate
What Makes Prothena (PRTA) a New Buy Stock
Prothena Corporation Plc (PTRA): Positioning Among Top Debt-Free Stocks